These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 21092441)

  • 21. In vitro activity of teicoplanin against gram-positive cocci.
    Allouch P; Pina P; Chaplain C; Delarbre JM; Geffroy F; Grasmick CP; Marcolin M; Morel A; Pangon B; Rio Y; Sédaillan A
    Pathol Biol (Paris); 2000 Oct; 48(8):792-5. PubMed ID: 11244609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of Gram-positive cocci.
    Tsao SM; Lin HC; Lee CM; Hsu GJ; Chen CM; Sun W; Liu YC; Jang TN; Cheng YJ; Lu PL; Chiang PC; Wang LS; Kung HC; Chuang YC; Shi ZY; Liu JW; Huang CH; Lu CT; Liao CH; Hsueh PR
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S184-7. PubMed ID: 19013352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Antimicrobial susceptibility of clinical isolates of aerobic Gram-positive cocci and anaerobic bacteria in 2006].
    Yamaguchi T; Yoshida I; Itoh Y; Tachibana M; Takahashi C; Kaku M; Kanemitsu K; Okada M; Horikawa Y; Shiotani J; Kino H; Ono Y; Baba H; Matsuo S; Asari S; Toyokawa M; Matsuoka K; Kusano N; Nose M; Murase M; Miyamoto H; Saikawa T; Hiramatsu K; Kohno S; Yanagihara K; Yamane N; Nakasone I; Maki H; Yamano Y
    Jpn J Antibiot; 2010 Dec; 63(6):431-56. PubMed ID: 21425596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Activity of vancomycin, teicoplanin and linezolid in methicillin resistant coagulase-negative Staphylococci isolates from paediatric blood cultures].
    Fajardo Olivares M; Hidalgo Orozco R; Rodríguez Garrido S; Gaona Álvarez C; Sánchez Silos RM; Hernández Rastrollo R; Martínez Tallo E; Cordero Carrasco JL
    Rev Esp Quimioter; 2012 Mar; 25(1):25-30. PubMed ID: 22488538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.
    Jones RN; Ross JE; Bell JM; Utsuki U; Fumiaki I; Kobayashi I; Turnidge JD
    Diagn Microbiol Infect Dis; 2009 Dec; 65(4):404-13. PubMed ID: 19913683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006.
    Zhanel GG; DeCorby M; Nichol KA; Wierzbowski A; Baudry PJ; Karlowsky JA; Lagacé-Wiens P; Walkty A; Mulvey MR; Hoban DJ;
    Diagn Microbiol Infect Dis; 2008 Sep; 62(1):67-80. PubMed ID: 18513913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Global in vitro activity of tigecycline and linezolid against Gram-positive organisms collected between 2004 and 2009.
    Dowzicky MJ; Chmelařová E
    Int J Antimicrob Agents; 2011 Jun; 37(6):562-6. PubMed ID: 21497066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci.
    Tünger A; Aydemir S; Uluer S; Cilli F
    Indian J Med Res; 2004 Dec; 120(6):546-52. PubMed ID: 15654141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program.
    Anderegg TR; Sader HS; Fritsche TR; Ross JE; Jones RN
    Int J Antimicrob Agents; 2005 Jul; 26(1):13-21. PubMed ID: 15967640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activities of tigecycline against clinical isolates from Shanghai, China.
    Zhang YY; Zhou L; Zhu DM; Wu PC; Hu FP; Wu WH; Wang F
    Diagn Microbiol Infect Dis; 2004 Dec; 50(4):267-81. PubMed ID: 15582300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Linezolid activity against clinical Gram-positive cocci with advanced antimicrobial drug resistance in Iran.
    Houri H; Kazemian H; Sedigh Ebrahim-Saraie H; Taji A; Tayebi Z; Heidari H
    J Glob Antimicrob Resist; 2017 Sep; 10():200-203. PubMed ID: 28735054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro activities of quinupristin/dalfopristin and eight other antimicrobial agents against 360 clinical isolates from Korea.
    Hwang SH; Kim MN; Pai CH; Huh DH; Shin WS
    Yonsei Med J; 2000 Oct; 41(5):563-9. PubMed ID: 11079615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16.
    Pfaller MA; Mendes RE; Duncan LR; Flamm RK; Sader HS
    J Antimicrob Chemother; 2018 Oct; 73(10):2748-2756. PubMed ID: 29982565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries.
    Jones RN; Fritsche TR; Sader HS; Ross JE
    Diagn Microbiol Infect Dis; 2007 Oct; 59(2):199-209. PubMed ID: 17908617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of daptomycin against Gram-positive cocci: the first multicentre study in Greece.
    Malli E; Spiliopoulou I; Kolonitsiou F; Klapsa D; Giannitsioti E; Pantelidi K; Pratti A; Panopoulou M; Grapsa S; Alepopoulou E; Neonakis I; Frantzidou F; Alexiou-Daniel S; Bakola D; Koutsia-Carouzou C; Malamou-Lada H; Zerva L; Vlahaki E; Kartali-Ktenidou S; Anastassiou ED; Petinaki E
    Int J Antimicrob Agents; 2008 Dec; 32(6):525-8. PubMed ID: 18774268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of macrolide resistance in Gram-positive cocci from Colombian hospitals: a countrywide surveillance.
    Reyes J; Hidalgo M; Díaz L; Rincón S; Moreno J; Vanegas N; Castañeda E; Arias CA
    Int J Infect Dis; 2007 Jul; 11(4):329-36. PubMed ID: 17320446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparative in vitro activity of daptomycin against gram-positive microorganisms: SENTRY surveillance program, Spain (2002-2006)].
    Loza E; Morosini MI; Pascual A; Tubau F; Alcalá J; Liñares J; Hernández-Bello JR; Baquero F; Perea E; Martín R; Jones RN; Cantón R;
    Enferm Infecc Microbiol Clin; 2008 Oct; 26(8):489-94. PubMed ID: 19094861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007-2009 study.
    Zhanel GG; Adam HJ; Low DE; Blondeau J; Decorby M; Karlowsky JA; Weshnoweski B; Vashisht R; Wierzbowski A; Hoban DJ;
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):291-306. PubMed ID: 21353957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular characterization of vancomycin-resistant Enterococcus spp. clinical isolates recovered from hospitalized patients among several medical institutions in China.
    Sun H; Wang H; Xu Y; Jones RN; Costello AJ; Liu Y; Li G; Chen M; Mendes RE
    Diagn Microbiol Infect Dis; 2012 Dec; 74(4):399-403. PubMed ID: 23099304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity of linezolid against Gram-positive cocci isolated in French hospitals as determined by three in-vitro susceptibility testing methods.
    Muller-Serieys C; Drugeon HB; Etienne J; Lascols C; Leclercq R; Nguyen J; Soussy CJ
    Clin Microbiol Infect; 2004 Mar; 10(3):242-6. PubMed ID: 15008946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.